Abstract:Chronic kidney disease (CKD) is a growing public health concern, affecting at least 1 in 7 adults in the United States, and accounting for a large proportion of healthcare spending. The risk of mortality rises steeply with declining kidney function, mostly due to cardiovascular-related deaths. Since CKD is asymptomatic in the early stages, diagnosis is sometimes delayed. However, early diagnosis is important for timely initiation of interventions to reduce disease progression, and to avoid the need for hospitalizations, dialysis, or kidney transplantation. This review focuses on the impact of sodium glucose transporter 2 inhibitors (SGLT2i) on CKD based on mechanistic and clinical trial evidence. These agents affect the kidneys through changes in sodium transport and metabolic factors that interfere with the primary pathological mechanisms shared by most kidney diseases. Following clinical trials of SGLT2i in patients with type 2 diabetes which demonstrated reductions in the risk of major adverse CV events, death, and hospitalizations for heart failure (HHF), and in patients with heart failure (HF) with and without diabetes which showed reductions in death and HHF, recent trials in patients with CKD have provided overwhelming support for the use of SGLT2i as foundational therapy across a broad spectrum of patients with CKD, regardless of diabetes status, primary kidney disease (except polycystic kidney disease), or kidney function. While clinical trials in CKD generally recruit patients with a high risk of events, patients at lower risk could also benefit from SGLT2i in terms of reduction of CKD progression, HF, and death, as well as other beneficial effects including reductions in blood sugar, body weight, and blood pressure. Chronic kidney disease (CKD) is a serious health problem that affects at least 1 in 7 adults in the United States. However, around 9 out of 10 adults with CKD are not aware that they have the condition. This is because people with CKD often have no symptoms, especially in the early stages of their condition. People with CKD have a higher risk of death and heart and/or kidney complications compared with people without the condition. It is important that doctors diagnose CKD as early as possible, so they can advise people about lifestyle changes and treatments that help to slow the progression of their CKD. Early diagnosis and intervention can reduce the chance that someone with CKD will be admitted to the hospital or eventually need dialysis or a kidney transplant. This article looked at a group of medicines called sodium-glucose cotransporter 2 (SGLT2) inhibitors that can be used to treat people with CKD. SGLT2 inhibitors were first developed to treat people with type 2 diabetes (T2D); however, further research has shown that these medicines can help to protect the kidneys and the heart in people with CKD with and without T2D. SGLT2 inhibitors can help to slow the decline in kidney function and lower the risk of death and hospitalizations in people with CKD. Research has shown that a wide range of people with CKD could benefit from treatment with SGLT2 inhibitors. This article describes how SGLT2 inhibitors can affect the body and the benefits of these medicines in people with CKD.

Role of Sodium-Glucose Co-Transporter 2 Inhibitors in Chronic Kidney Disease, Congestive Heart Failure and Stroke-A Review and Clinical Guide for Healthcare Professionals

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence

Efficacy and safety of SGLT2 inhibitors in nondiabetic patients with CKD: a review of recent evidence

Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus

Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?

Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review

SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients

A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease

SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review

Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science

Slowing the progression of diabetic and non‐diabetic kidney disease: A summary of the current evidence base for sodium‐glucose co‐transporter‐2 inhibitors

SGLT2 Inhibitors: A New Therapeutical Strategy to Improve Clinical Outcomes in Patients with Chronic Kidney Diseases

Cardiovascular Disease Management With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Cardiology Primer

Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Heart Failure in Patients With Type 2 Diabetes Mellitus: A Systematic Review

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Cardiovascular Outcomes: A Review of Literature

Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors

Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases

SGLT2 inhibitors across the spectrum of chronic kidney disease: a narrative review

Diabetes and Cardiorenal Complications: A Clinical Review of Existing Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors.